Compare Cytokinetics Inc (CYTK) vs Devon Energy Corp (DVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Devon Energy Corp — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Devon Energy Corp trades at $48.26 (market cap $53.81B). The key difference: Devon Energy Corp is far larger — about 6.2× Cytokinetics Inc's market cap, and Devon Energy Corp pays a 2.62% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Devon Energy Corp for 136 Days on average.
| CYTK | DVN | |
|---|---|---|
Market Cap | $8.62B | $53.81B |
Volume | 2,594,626 | 11,556,740 |
Sector | Health | Energy |
52-Week High | $87.26 | $52.07 |
52-Week Low | $54.76 | $31.74 |
Typical Hold Time | 19 Days | 136 Days |
Enterprise Value | $8.72B | $64.55B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Devon Energy (DVN) trades at $48.92, up 2.17% today, with strong analyst support showing 72% buy ratings and a $62.53 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal solid profitability with 16.67% net margins and attractive valuation at 10.63 P/E. Recent activist pressure from Toms Capital for strategic alternatives and potential asset sales with BP creates near-term catalysts.
DVN presents compelling value with upside potential to analyst targets, though faces execution risks on asset sales and oil price volatility. The company's improving cash flow generation and Permian Basin focus support the bullish case, but investors should monitor activist developments and energy market conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
